Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Vericel, with a price target of $58.00. Newitter cove...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VCEL	$43.71	-1.11%	89.49K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VCEL	$43.71	-1.1%	89.49K
3
4
5
6

VCEL

Get Vericel Corporation Data in Excel

Get Vericel Corporation Data in Excel